We are live on ! Find out more
BAMS

Bellevue Asset Management (Switzerland) Portfolio holdings

AUM $656M
1-Year Est. Return 11.45%
This Fund
S&P 500
This Quarter Est. Return
+4.85%
1 Year Est. Return
+11.45%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$721M
AUM Growth
+$3.8M
Cap. Flow
-$22.4M
Cap. Flow %
-3.1%
Top 10 Hldgs %
29.13%
Holding
154
New
13
Increased
38
Reduced
45
Closed
15

Top Buys

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$6.22M
2
COR icon
Cencora
COR
+$5.63M
3
ILMN icon
Illumina
ILMN
+$5.46M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$4.98M
5
PRGO icon
Perrigo
PRGO
+$4.77M

Top Sells

Rank Stock Value
1
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$18.9M
2
BAX icon
Baxter International
BAX
+$9.56M
3
CNC icon
Centene
CNC
+$8.47M
4
LCI
Lannett Company, Inc.
LCI
+$6.61M
5
MOH icon
Molina Healthcare
MOH
+$6.39M

Sector Composition

Rank Sector Weight
1 Healthcare 90.06%
2 Financials 0.8%
3 Industrials 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELV icon
51
Elevance Health
ELV
$86.4B
$4.92M 0.68%
30,000
– –
JNJ icon
52
Johnson & Johnson
JNJ
$627B
$4.87M 0.68%
50,000
+10,000
+25% +$1M
EW icon
53
Edwards Lifesciences
EW
$53.2B
$4.86M 0.67%
204,600
+117,600
+135% +$2.65M
CLVS
54
DELISTED
Clovis Oncology, Inc.
CLVS
$4.84M 0.67%
55,100
+13,000
+31% +$1.11M
AGIO icon
55
Agios Pharmaceuticals
AGIO
$1.95B
$4.56M 0.63%
41,000
-17,000
-29% -$1.83M
HUM icon
56
Humana
HUM
$46.6B
$4.5M 0.62%
23,500
-1,500
-6% -$278K
INSY
57
DELISTED
Insys Therapeutics, Inc.
INSY
$4.31M 0.6%
+120,000
New +$3.74M
ACAD icon
58
Acadia Pharmaceuticals
ACAD
$5.06B
$4.23M 0.59%
101,000
-130,000
-56% -$5.03M
ARIA
59
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$4.09M 0.57%
495,000
-34,000
-6% -$301K
TFX icon
60
Teleflex
TFX
$6.01B
$4.06M 0.56%
30,000
– –
BMY icon
61
Bristol-Myers Squibb
BMY
$133B
$3.99M 0.55%
60,000
– –
MRK icon
62
Merck
MRK
$321B
$3.98M 0.55%
73,360
+31,440
+75% +$1.76M
CERN
63
DELISTED
Cerner Corp
CERN
$3.8M 0.53%
55,000
-11,000
-17% -$770K
XENT
64
DELISTED
Intersect ENT, Inc
XENT
$3.72M 0.52%
130,000
+56,200
+76% +$1.47M
HCA icon
65
HCA Healthcare
HCA
$89.3B
$3.63M 0.5%
40,000
-27,000
-40% -$2.16M
VAR
66
DELISTED
Varian Medical Systems, Inc.
VAR
$3.54M 0.49%
47,896
-5,702
-11% -$446K
BLUE
67
DELISTED
bluebird bio
BLUE
$3.37M 0.47%
1,544
+463
+43% +$943K
PFE icon
68
Pfizer
PFE
$154B
$3.35M 0.47%
105,400
-84,320
-44% -$2.75M
ACHN
69
DELISTED
Achillion Pharmaceuticals
ACHN
$3.33M 0.46%
376,000
-70,000
-16% -$662K
COO icon
70
Cooper Companies
COO
$14.8B
$3.29M 0.46%
74,000
– –
NBIX icon
71
Neurocrine Biosciences
NBIX
$16.7B
$3.1M 0.43%
65,000
+25,000
+63% +$1.06M
HOLX
72
DELISTED
Hologic
HOLX
$3.08M 0.43%
81,000
– –
MGNX icon
73
MacroGenics
MGNX
$259M
$3.08M 0.43%
81,000
+66,000
+440% +$2.17M
XRAY icon
74
Dentsply Sirona
XRAY
$2.36B
$3.01M 0.42%
58,400
+16,400
+39% +$849K
MASI
75
DELISTED
Masimo
MASI
$2.91M 0.4%
75,000
+25,000
+50% +$896K
1 2
3
4 5

Similar funds

VFAM
Valley Forge Asset Management King Of Prussia, Pennsylvania $645M AUM 5.8% 1-Year Est. Return
MSU
Maple Securities USA Jersey City, New Jersey $672M AUM 1.03% 1-Year Est. Return
PSI
Pinnacle Summer Investments Fairfax, Virginia $678M AUM 9.5% 1-Year Est. Return
SFP
Santa Fe Partners Santa Fe, New Mexico $608M AUM 8.76% 1-Year Est. Return
MCM
Mazama Capital Management Portland, Oregon $544M AUM 9.52% 1-Year Est. Return
NMIS
Northwestern Mutual Investment Services Milwaukee, Wisconsin $525M AUM 2.45% 1-Year Est. Return
SM
Stratton Management King Of Prussia, Pennsylvania $824M AUM 1.57% 1-Year Est. Return
ZAM
Zenit Asset Management Stockholm, Sweden $450M AUM 8.32% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s Q2 2015 Portfolio in Review

As of Q2 2015, Bellevue Asset Management (Switzerland) held 154 positions worth $721M, up 0.53% from $717M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Asset Management (Switzerland) withdrew a net $22.4M in Q2 2015, closing 15 positions and reducing 45 holdings. Its most notable exit was CATAMARAN CORP COM STK (CDA), an estimated $18.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Bellevue Asset Management (Switzerland) opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $5.21M.

  • Bellevue Asset Management (Switzerland)'s largest Q2 2015 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 150,000 shares worth $5.21M.
  • Bellevue Asset Management (Switzerland) added most to Endo International plc in Q2 2015, an estimated $6.22M increase.
  • Bellevue Asset Management (Switzerland)'s biggest Q2 2015 reduction was Centene, cutting an estimated $8.47M.
  • Bellevue Asset Management (Switzerland) fully exited CATAMARAN CORP COM STK (CDA) in Q2 2015, selling an estimated $18.9M.
  • Bellevue Asset Management (Switzerland)'s ten largest holdings make up 29% of its $721M portfolio in Q2 2015.
  • Bellevue Asset Management (Switzerland) opened 13 new positions and closed 15 in Q2 2015.
  • Bellevue Asset Management (Switzerland)'s portfolio value rose 0.53% quarter-over-quarter to $721M.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q2 2015, filed 12 Aug 2015.